AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03904953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise programme
Description: Stretching of erector spine, hip flexors, hamstring muscles and gastro-soleus muscles; back-strengthening of cervical, thoracic and lumbar spine and posture exercises will be taught to the patients in the first session and the patients will be requested to repeat the exercises three times a week for 8 weeks individually at home.
Study NCT00536640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 80 mg/m2 i.v. on day 1 (three-week cycle) until tumor progression for a maximum of 6 cycles. (The administration of 40 mg/2 Cisplatin on day 1 and day 8 is also possible)
Study NCT01933230 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Excel Cryo Cooling System
Description: An Excel Cryo Cooling System collar will be place around the neck for two hours. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level, and pressure both in the head and in the blood.~2 hour neck cooling period
Study NCT00446472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regranex®
Description: Regranex gel will be used for a total of 16 weeks
Study NCT00446472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel
Description: Placebo hydrogel will be applied for 16 weeks
Study NCT04580758 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Fractional laser with PRP fluid or PRP gel
Description: 20 participants divided into 2 groups of 10 10 participants will do Fractional laser with PRP fluid sessions and 10 participants will do Fractional laser with PRP gel
Study NCT02117895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Celiac plexus resection
Description: Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
Study NCT03147495 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiograph.
Description: Standing anteroposterior knee radiographs and special proximal tibiofibular joint radiographs will be taken for the participants in both groups. The standing anteroposterior knee radiographs will be obtained with the knee extended. The proximal tibiofibular joint radiographs will be acquired with the knee of the participants in approximately 45°-60° of internal rotation.
Study NCT02117895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatectomy
Description: Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
Study NCT02117895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatectomy
Description: Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
Study NCT03593135 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple Cider Vinegar and tablet Tagipmet (Metformin + Sitagliptin group)
Description: 15ml apple cider vinegar (American garden organic vinegar) (containing 5% acetic acid) mixed in 200ml water during meal at night time, for 3 months and tablet Tagipmet 50mg/1000mg (Metformin + Sitagliptin group) twice a day. NOTE medical treatment is our inclusion criteria.
Study NCT03593135 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water with Apple Cider vinegar flavor and tablet Tagipmet (Metformin + Sitagliptin group)
Description: Flavor of apple cider vinegar in 200 ml water is added and given to have a placebo effect and tablet Tagipmet 50mg/1000mg (Metformin + Sitagliptin group) twice a day. NOTE medical treatment is our inclusion criteria.
Study NCT00221715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: femoropopliteal artery bypass
Description: Bypass by autologous saphenous vein
Study NCT00221715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: femoropopliteal artery bypass
Description: bypass by dacron or PTFE Prosthesis
Study NCT01552616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal-aided muscle activation
Description: Thermal-aided muscle activation therapy will be provided to patients twice daily. Treatment will begin within 24 hours of admission and continue until patients are significantly ambulatory.
Study NCT02980146 — intervention group
Intervention type: OTHER
Intervention: Non interventional study
Study NCT01094353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-sling
Description: The minisling is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
Study NCT01094353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transobturator
Description: Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
Study NCT04421872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: receiving general anesthesia
Description: patients receiving surgery under general anesthesia
Study NCT01810068 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser enucleation of the prostate
Description: Laser assisted enucleation of the prostatic adenoma
Study NCT01810068 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar transurethral resection of the prostate
Description: using the monopolar electrocautery to resect the prostate adenoma
Study NCT01810068 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar transurethral resection of the prostate
Description: using the bipolar electrocautery to resect the prostate adenoma
Study NCT01810068 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Diagnostic cystoscopy
Description: Cysto-urethroscopy
Study NCT04700657 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: corneal sensation test
Description: Thorough ocular surface study including corneal sensation test in the GVHD group, comparing to the normal control group
Study NCT03723811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJP002 BID
Description: 1 drop b.i.d for 12 weeks
Study NCT03823352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol
Description: Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
Study NCT01585428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
Study NCT01585428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml in 5% dextrose in water (D5W) over 1 hr.
Study NCT03723811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJP002 QID
Description: 1 drop q.i.d for 12 weeks
Study NCT01585428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
Study NCT01585428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
Study NCT01084174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut powder
Description: Delivered orally
Study NCT01084174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut extract
Description: Delivered sublingually
Study NCT01084174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo extract
Description: Delivered sublingually
Study NCT01084174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo powder
Description: Delivered orally
Study NCT00607529 — intervention group
Intervention type: OTHER
Intervention: hand-held POC creatinine analyzer-blood test
Description: This study will require the collection of a finger-puncture capillary blood specimen in addition to one green stoppered heparin containing collection tube. This is taken pre-therapy. The capillary whole blood specimen will be used to perform a creatinine determination on the investigational hand-held creatinine analyzer using special test strips for the analysis.
Study NCT01879501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Vision Self-Management Program
Description: The program has been describe above.
Study NCT00869206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV
Study NCT03578289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemental Health - CBT
Description: The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
Study NCT01594125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib high dose
Description: twice daily oral dosing
Study NCT01594125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib low dose
Description: twice daily oral dosing
Study NCT01594125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib medium dose
Description: twice daily oral dosing
Study NCT01404390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY80-6946
Description: 0.4mg/ kg, iv, day 1,8 and 15, every 28 days
Study NCT01404390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY80-6946
Description: 0.8mg/ kg, iv, day 1,8 and 15, every 28 days
Study NCT00503009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate/salmeterol
Description: comparator
Study NCT00503009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: Comparator
Study NCT00503009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT04688307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Motivational interviewing for smoking reduction and adherence to diet and physical activity for obtaining ideal body weight
Study NCT03327298 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: pedicle screw fixation
Description: One hundred forty four screws were placed in the lumbosacral pedicles of 32 patients using free hand technique depending on direct visualization of the pedicles, roots, and intervertebral disc ( IVD) after doing full laminectomy, then postoperative CT was done for evaluation of pedicle violation.
Study NCT03502226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored feedback
Description: Electronic feedback based on participants stage of change which provided risk reduction behavior regarding their sexual health including use of condoms, contraceptions, and STI testing.
Study NCT02150096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous ultrasound group
Description: the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
Study NCT02150096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pulsed ultrasound group
Description: the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
Study NCT02150096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy group
Description: the group will be treated with 3 J 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
Study NCT01197053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epicutaneous Immunotherapy
Description: 100 mcg peanut proteins (active arm) applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
Study NCT01197053 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo of peanut
Description: placebo applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
Study NCT03274414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin should be administered on day 1 (+/- 3 days) of the start of radiotherapy and then every 3 weeks (unless there is a delay for safety concerns such as neutropenia) for a total of 3 cycles. 100 mg/m\^2 (dose reductions after the first cycle allowed for toxicity)
Study NCT03274414 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Proton Radiotherapy
Description: Proton therapy treatment will follow the National Cancer Institute's Guidelines for the Use of Proton Radiation Therapy in NCI-Sponsored Cooperative Group Trials. Proton therapy techniques may include passively scattered or scanning or pencil beam technology.
Study NCT03274414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Resection
Description: In brief, an endoscope is used and two surgeons perform the intervention in a binostril manner. Tumor is generally resected with an emphasis on identification of the attachments in the paranasal sinuses, nasal cavity, or skull base.
Study NCT03274414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin and etoposide
Description: If the final surgical pathology report shows SNUC, at the discretion of the treating medical oncologist, the patient will receive an addition of etoposide chemotherapy to cisplatin chemotherapy. The dose of cisplatin will be decresed from 100 mg/m2 to 60 mg/m2. Cisplatin should be administered on days 1-2, 21-22 and 42-43 at a dose of 60 mg/m2 and Etoposide should be administered at days 1-3, 21-23, and 42-44 at a dose of 120 mg/m2.
Study NCT04379089 — intervention group
Intervention type: OTHER
Intervention: Observational study only
Description: No Intervention
Study NCT00022633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00022633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT02054416 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ArtAssist© Device
Description: The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
Study NCT02054416 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ArtAssist© Device
Description: The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
Study NCT01012856 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Depression
Description: 22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on cognitive restructuring without emotion-focused interventions
Study NCT01012856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-Based Cognitive Therapy for Depression
Description: 22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on emotion-focused interventions
Study NCT05868863 — intervention group
Intervention type: OTHER
Intervention: datas of medical record.
Description: Analysis datas of medical record:~* Feasibility of the technique~* Safety of the technique with evaluation by Cardiovascular and Interventional Radiological Society of Europe (CIRSE) scale~* Analgesic intake before and after the procedure~* Functional criteria: early rising, walking
Study NCT03549871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fitusiran
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study NCT03549871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPA prophylaxis
Description: Pharmaceutical form: solution for injection Route of administration: Intravenous
Study NCT03549871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor (FVIII or FIX) prophylaxis
Description: Pharmaceutical form: solution for injection Route of administration: Intravenous
Study NCT02682589 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: A traditional midline incision is made through the abdominal wall and a colectomy with CME is performed.
Study NCT03723811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SJP002 Placebo 1
Description: 1 drop q.i.d for 12 weeks
Study NCT03723811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SJP002 Placebo 2
Description: 1 drop q.i.d for 12 weeks
Study NCT01569178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow aspiration and intracoronary reinfusion
Description: Bone marrow-derived progenitor cells are obtained from 50ml bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique
Study NCT04593563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Single 5 capsule oral psilocybin dose: 25mg: 5 x 5 mg capsules.
Study NCT01643655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Tissue derived MSCs Transplantation
Description: Into the Femoral Head infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 cells/3mL
Study NCT00703079 — intervention group
Intervention type: DRUG
Intervention: Octreotide-LAR or lanreotide
Description: Treated with octreotide-LAR will be given at dosages of 10-40 mg/q28d and treatment with lanreotide-SR at dosages of 60-120 mg/q28d. The dosages are up-titrated to control GH and IGF-I levels
Study NCT00703079 — intervention group
Intervention type: PROCEDURE
Intervention: Transsphenoidal adenomectomy
Description: Removal of pituitary adenomas via one-nostril transsphenoidal approach and endoscopy-assisted.
Study NCT04317430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: lactose tablets
Study NCT02106884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Study NCT01607086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cherry lamotrigine ODT
Description: 25mg, taken orally on one study visit
Study NCT01607086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cherry Placebo
Description: Taken orally on one study visit
Study NCT03913793 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise based-cardiac rehabilitation (EB-CR) program
Description: The exercise group underwent an outpatient EB-CR program (phase II) according to the American College of Sports Medicine guidelines for exercise prescription for cardiac patients.\[19\] Sessions were 3 days/week for 8 weeks. The program included: (1) Warm up (10 minutes): stretching exercises. (2) Aerobic exercise training using treadmill (30 - 60 minutes/session): with target heart rate (HR) at 45 - 75% of HR reserve. The maximal HR (HR max) was derived from that obtained during exercise stress test (EST). Patients who had ischemic/arrhythmic manifestations during EST, exercise intensity was prescribed at a HR below the ischemic threshold (10 beats below). (3) Cool down (10 minutes): light intensity treadmill walking. Supervision was provided according to the risk status of each patient that was determined according to the American Association of cardiovascular and Pulmonary Rehabilitation criteria for risk stratification.
Study NCT01265173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefotaxime
Description: 3 g
Study NCT01265173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: 2 g
Study NCT01690247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional plus UC-MSC
Description: Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
Study NCT01690247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional plus placebo
Description: Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
Study NCT03468257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pavlovian Conditioning
Description: Imagining a stressful event, engaging in progressive muscle relaxation, and eating fruit